UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

British journal of haematology, 2008-05, Vol.141 (4), p.512-516

2008

Volltextzugriff (PDF)

Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients

British journal of haematology, 2020-07, Vol.190 (2), p.e64-e67

2020

Volltextzugriff (PDF)

Thalidomide in multiple myeloma: Current status and future prospects

British journal of haematology, 2003-01, Vol.120 (1), p.18-26

2003

Volltextzugriff (PDF)

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat

Clinical lymphoma, myeloma and leukemia, 2018-08, Vol.18 (8), p.501-507

2018

Volltextzugriff (PDF)

NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma

Blood advances, 2022-09, Vol.6 (17), p.5152-5159

2022

Volltextzugriff (PDF)

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Clinical cancer research, 2017-11, Vol.23 (21), p.6430-6440

2017

Volltextzugriff (PDF)

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

Clinical hematology international, 2021-03, Vol.3 (1), p.27-33

2021

Volltextzugriff (PDF)

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma

Journal of clinical oncology, 2019-07, Vol.37 (19), p.1617-1628

2019

Volltextzugriff (PDF)

Mutation of CEBPA in Familial Acute Myeloid Leukemia

The New England journal of medicine, 2004-12, Vol.351 (23), p.2403-2407

2004

Volltextzugriff (PDF)

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

British journal of haematology, 2009-03, Vol.144 (6), p.895-903

2009

Volltextzugriff (PDF)

PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

British journal of haematology, 2005-06, Vol.129 (6), p.755-762

2005

Volltextzugriff (PDF)

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

British journal of haematology, 2021-05, Vol.193 (3), p.e19-e22

2021

Volltextzugriff (PDF)

Durable graft‐versus‐leukaemia effects without donor lymphocyte infusions – results of a phase II study of sequential T‐replete allogeneic transplantation for high‐risk acute myeloid leukaemia and myelodysplasia

British journal of haematology, 2018-02, Vol.180 (3), p.346-355

2018

Volltextzugriff (PDF)

Toward a better management of older patients with acute myeloid leukemia

Future oncology (London, England), 2015-03, Vol.11 (5), p.715-718

2015

Volltextzugriff (PDF)

Long‐term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non‐myeloablative conditioning without T cell depletion

British journal of haematology, 2013-08, Vol.162 (4), p.525-529

2013

Volltextzugriff (PDF)

Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

British journal of haematology, 2007-06, Vol.137 (5), p.429-435

2007

Volltextzugriff (PDF)

Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease

Journal of clinical oncology, 2006-05, Vol.24 (14), p.e23-e25

2006

Volltextzugriff (PDF)

A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy

Leukemia research, 2006-04, Vol.30 (4), p.373-378

2006

Volltextzugriff (PDF)

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up

British journal of haematology, 2014-12, Vol.167 (5), p.724-726

2014

Volltextzugriff (PDF)

Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract

British journal of haematology, 2012-05, Vol.157 (3), p.403-407

2012

Volltextzugriff (PDF)

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience

British journal of haematology, 2009-09, Vol.146 (5), p.574-576

2009

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Aktive Filter

KollektionNexis Uni

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(71)
Berichte
(1)

Sprache

Englisch
(72)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Humans
(46)
Hematology
(38)
Male
(27)
Middle Aged
(27)
Female
(25)
Adult
(24)
Aged
(21)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Multiple Myeloma - Drug Therapy
(15)
Treatment Outcome
(13)
Hematologic And Hematopoietic Diseases
(12)
Multiple Myeloma
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Disease-Free Survival
(11)
Bortezomib
(10)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(10)
Multiple Myeloma - Mortality
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thalidomide in multiple myeloma: Current status and future prospects

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat

NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma

Mutation of CEBPA in Familial Acute Myeloid Leukemia

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Durable graft‐versus‐leukaemia effects without donor lymphocyte infusions – results of a phase II study of sequential T‐replete allogeneic transplantation for high‐risk acute myeloid leukaemia and myelodysplasia

Toward a better management of older patients with acute myeloid leukemia

Long‐term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non‐myeloablative conditioning without T cell depletion

Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease

A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up

Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience

Aktive Filter

Suchergebnisse filtern